About fibrosing alveolitis

What is fibrosing alveolitis?

Fibrosing Alveolitis, also known as Pulmonary Fibrosis, is a lung condition that affects the tissues that support the air sacs. As a result, it is more difficult for them to absorb the necessary oxygen for respiration. The lung tissues thicken and scar in this condition, resulting in decreased elasticity of the organ and making breathing difficult.

What are the symptoms for fibrosing alveolitis?

Patients' complaints for idiopathic fibrosing alveolitis are extremely common, and a careful examination of them leads to the diagnosis: Shortness of breath is the most common and persistent symptom of the condition. Shortness of breath is less noticeable at first, but as the condition worsens, the patient becomes unable to walk, serve himself, or even speak. Dyspnea becomes more noticeable as the condition progresses and worsens. Patients complain about their inability to take deep breaths, as well as the persistent nature of their Dyspnea and the absence of suffocation crises. Progressive Dyspnea patients gradually reduce their activity and seek a more passive lifestyle. Cough is the second most common symptom of idiopathic fibrosing alveolitis, affecting approximately 90% of patients. Cough, on the other hand, is not the first symptom; it appears later, usually during the course of a severe clinical picture of idiopathic fibrosing alveolitis. Coughing is usually dry, but in 10% of patients, it is accompanied by mucous sputum separation; chest discomfort - is felt by half of the patients, and it is most commonly located in the epigastric region on both sides, and it usually worsens with deep inspiration; Weight loss is a common symptom of idiopathic fibrosing alveolitis, and it causes concern in patients as the disease progresses; the severity and duration of the diseased process in the lungs determine the extent of weight loss. General weakness, fatigue, and decreased performance are common symptoms in all patients, though they become more pronounced as the disease progresses. Morning stiffness and Joint pain are uncommon complaints, but they can be severe in severe conditions.

What are the causes for fibrosing alveolitis?

Idiopathic fibrosing alveolitis is still not well understood. The following etiological factors are currently being discussed: Viruses that are "undetectable" or "slow," such as the hepatitis C virus and the human immunodeficiency virus, are the most common. Viruses are thought to play a dual role in the progression of idiopathic fibrosing alveolitis: they are the primary cause of lung tissue deterioration, and the virus then multiplies in the already damaged tissues, leading to disease progression.

Viruses have also been shown to interact with genes that regulate cell growth, resulting in increased collagen formation and fibro-oocyte production. In addition, viruses can exacerbate pre-existing chronic inflammation. Idiopathic fibrosing alveolitis has been linked to extensive professional contact with metal and wood dust, brass, lead, steel, and various types of inorganic dust, such as asbestos and silicon. It's not impossible that aggressive etiological elements contributed to the aetiology.

It is important to note, however, that these workplace conditions cause pneumoconiosis and, in the case of idiopathic fibrosing alveolitis, almost certainly contribute to its development. The fact that family members can become ill emphasises the significance of hereditary predisposition. Hereditary polymorphisms in genes encoding proteins involved in antigen processing and presentation to T cells are thought to underpin the genetic predisposition to idiopathic fibrosing alveolitis. The major pathophysiological features of idiopathic fibrosing alveolitis are broad intermittent lung tissue inflammation and the subsequent development of an intensive and widespread fibrotic process. Pulmonary interstitial tissue is a type I collagen-based connective tissue matrix found in the alveolar wall that is bordered by epithelial and endothelial basal membranes. Both sides of the membrane are filled with alveolar epithelium, which is common for two adjacent alveoli.

What are the treatments for fibrosing alveolitis?

Idiopathic fibrosing alveolitis is a degenerative disease that causes alveolar fibrosis, incrusctive lung tissue, and progressive respiratory limitation. Glucocorticoids and D-penicillamine are the most commonly used treatments for fibrosing alveolitis. The dosage of these drugs is determined by the disease's stage. Glucocorticoids are recommended during the interstitial edoema and alveolitis phases (this stage is detected clinically and radiologically). They have anti-inflammatory and immunosuppressive properties, and they help to prevent fibrosis.

Patients with early-stage idiopathic fibrosing alveolitis are given 40-50 mg of prednisolone for 3-10 days, then the dose is gradually reduced (depending on the effect) for 6-8 months to keep the condition stable (2.5-5 mg per day). In general, the medication is effective for 18-20 months. When the deteriorating phase has progressed to the level of interstitial fibrosis, D-penicillamine in combination with prednisone is administered, with a starting dose of 15-20 mg per day.

Copper levels in the bloodstream of people with fibrosing alveolitis were found to be higher, possibly contributing to the collagenization of the interstitial lung stroma. D-penicillamine inhibits copper-containing aminoxidase, which lowers copper levels in the blood and lungs, preventing collagen development and synthesis. D-penicillamine also suppresses the immune system. Prescribe D-penicillamine at 0.3 g per day for 4-6 months, then 0.15 g per day for 1-1.5 years, in the chronic course of the disease without pronounced exacerbations.

What are the risk factors for fibrosing alveolitis?

While the cause of fibrosing alveolitis is unknown in most cases, medical experts believe that a number of factors can increase a person's risk of developing the disease. Examples include smoking and long-term dust exposure, such as from working with wood or metal or as a miner. A remarkable feature of fibrosing alveolitis is that men are nearly twice as likely as women to develop it. Men, on the other hand, are less likely to visit the doctor on a regular basis than women. So, if you have any of the fibrosing alveolitis symptoms listed above, you should seek medical attention immediately. A dry cough or shortness of breath may appear minor, but do not dismiss them. They could indicate something more serious. 

Is there a cure/medications for fibrosing alveolitis?

There is currently no cure for fibrosing alveolitis. However, depending on how the individual is affected by the illness, it can be treated. This could include medication as well as oxygen therapy, which can help people suffering from severe symptoms get more oxygen than they would otherwise. Oxygen therapy, or supplemental oxygen for home use, became a strong recommendation in patients with severely low oxygen levels at rest. Although there is no evidence that oxygen therapy improves lifespan in IPF patients, there is some evidence that it improves exercise capacity. Lung rehabilitation, which consists of physical and respiratory activities designed to help people manage their symptoms, may also be used as part of the treatment. Candidates for lung transplantation may be patients who are physically capable of undergoing a major transplant operation. When compared to those who remain on the waiting list, lung transplantation has been shown to reduce the risk of death in IPF patients by 75%. A bad prognosis combined with the lack of a curative treatment has fueled a long-term research effort to find effective treatments. A recent trial result indicates that progress has been made. Interferon gamma-1, bosentan, ambrisentan, and anticoagulants were all studied for IPF in the past, but they are no longer considered appropriate therapeutic options. Many previous studies were based on the assumption that IPF is an inflammatory disease. (NAC) is a precursor to glutathione, an antioxidant. Large doses of NAC may be able to correct an oxidant-antioxidant imbalance that develops in IPF patients' lung tissue.

Video related to fibrosing alveolitis